Regulation - Aegerion Pharmaceuticals


Current filters:

Aegerion Pharmaceuticals

Popular Filters

Aegerion gains European approval for rare disease drug


The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

FDA approves Aegerion's new orphan drug Juxtapid for rare cholesterol disorder


The US Food and Drug Administration has recently approved emerging US biotech firm Aegerion Pharmaceuticals'…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularJuxtapidlomitapideNorth AmericaRare diseasesRegulation

US FDA approves ThromboGenics' Jetrea; advisory backing for Aegerion's lomitapide


Belgian drugmaker ThromboGenics NV (Euronext Brussels: THR) yesterday received US Food and Drug Administration…

Aegerion PharmaceuticalsCardio-vascularJetrealomitapideNorth AmericaOphthalmicsPharmaceuticalRegulationThromboGenics

Aegerion files for lomitapide approval in USA and Europe


Emerging US biotech firm Aegerion Pharmaceuticals (Nasdaq: AEGR) has submitted a New Drug Application…

Aegerion PharmaceuticalsBiotechnologyEuropelomitapideNorth AmericaRare diseasesRegulation

Back to top